Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: ( A ) Schematic overview of drug screening comparing non-malignant melanocytes (NHEM-hTERT) and the BRAF V600E-mutated Mel-DCC-11 cell line. The number of drugs that reduced cell viability by more than 50% is indicated, with comparisons selected based on viability values shown in ( B ). ( B ) Viability values of NHEM-hTERT plotted against the viability values of Mel-DCC-11 for all tested 315 compounds at 1 µM. Each dot represents the mean value of two biological replicates. The dotted lines separate the toxic (+/+), Mel-DCC-11-specific (−/+), and Mel-DCC-unspecific (+/−) drugs, which reduce the viability to less than 50% in each group. ( C ) Heatmap of viability values for top-scoring drugs affecting NHEM-hTERT and Mel-DTC-11 (upper panel, n = 12 drugs) or selectively inhibiting Mel-DCC-11 viability by more than 50% (lower panel, n = 19 drugs). The mean viability values of two biological replicates are shown. .

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Drug discovery

Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: ( A ) Upper graph: Vemurafinib treatment of Mel-DCC CLs. Cells were incubated with doses ranging from 0.025 µM to 5 µM Vemurafenib for 5 days. Cell viability is shown for BRAF wt Mel-DCC-07 (red, n = 4), BRAF V600K-mutated Mel-DCC-13 (gray, n = 4), and BRAF V600E-mutated Mel-DCC-02 (black, n = 5). Lower graph: Binimetinib treatment of Mel-DCC CLs. Cells were incubated with Binimetinib at doses ranging from 0.001 µM to 1 µM for 5 days. Cell viability is shown for NRAS Q61R-mutated Mel-DCC-04 (red, n = 4), NRAS T58I-mutated Mel-DCC-07 (gray, n = 6), and NRAS Q61K-mutated Mel-DCC-01 (black, n = 4). Each dot represents the mean value ± SD of biological replicates. ( B ) Generation of a Vemurafenib-resistant BRAF-mutated melanoma cell line (Mel-DCC-11-R). Resistance was generated through stepwise exposure to increasing concentrations of Vemurafenib over the indicated timeframe. Sensitivity of Mel-DCC-11 (black, n = 3) vs. Mel-DCC-11-R (red, n = 5) to Vemurafenib is shown. Each dot represents the mean value ± SD of biological replicates. ( C ) Outcome of experimental drug testing with 315 anti-cancer drugs on BRAF V600E-mutated Mel-DCC-11 and Vemurafenib-resistant Mel-DCC-11-R, alone or in combination with 8 µM Vemurafenib (Mel-DCC-11-R + V). The number of drugs that reduce cell viability to less than 80% is indicated. ( D ) Heatmap showing the drug-induced reduction of the viability in the Vemurafenib-restistant CL, screened in the presence (Mel-DCC-11-R + V) or absence (Mel-DCC-11-R) of Vemurafenib, alongside the parental Vemurafenib-sensitive Mel-DCC-11, screened without Vemurafenib. The mean viability of two biological replicates is shown. .

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Incubation, Generated, Sensitivity, Cell Viability Assay, Drug discovery

Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Recombinant, Sequencing, Diagnostic Assay, Membrane, Tissue, DNA Labeling, Microarray, Drug discovery, Cell Viability Assay, Luminescence Assay, Staining, Software, Extraction, Analysis

Journal: Biology Open

Article Title: Effects of β4 integrin expression on microRNA patterns in breast cancer

doi: 10.1242/bio.20121628

Figure Lengend Snippet: ( A ) qNPA microarray was performed in triplicate on MCF10CA1a siCtrl cells and MCF10CA1a siβ4 cells at 72 hours post-transfection. The heat map depicts the 44 miRNAs undergoing a statistically significant change in expression following transient depletion of β4 subunit in this system. ( B ) qNPA microarray was performed in triplicate on two subclones of the MDA-MB-435/β4 transfectants (3A7 and 5B3), and two subclones of the MDA-MB-435/mock transfectants (6D2 and 6D7). The heat map depicts the 50 miRNAs undergoing a statistically significant change in expression following introduction of the β4 subunit into this system. ( C ) qNPA microarray was performed in triplicate on ten β4 positive and ten β4 negative invasive breast carcinomas. The heat map depicts the 74 miRNAs differentially expressed between tumor subsets. For all array analyses, a p-value < 0.05 and a ±1.2-fold change cut-off was applied. Color was assigned to each miRNA based on relative expression across samples.

Article Snippet: A novel qNPA based miRNA Microarray high throughput platform from High Throughput Genomics (HTG Molecular Diagnostics, Inc.; Tuscon, AZ, USA) was used to study 1050 mature miRNAs in human, rat, and mouse based upon the Sanger miRBase release 9.1.

Techniques: Microarray, Transfection, Expressing

Journal: Biology Open

Article Title: Effects of β4 integrin expression on microRNA patterns in breast cancer

doi: 10.1242/bio.20121628

Figure Lengend Snippet: ( A ) Venn diagram of overlapping miRNAs that undergo differential expression in response to β4 across all three arrays. ( B ) Venn diagram of overlapping miRNA families that undergo differential expression in response to β4 across all three arrays.

Article Snippet: A novel qNPA based miRNA Microarray high throughput platform from High Throughput Genomics (HTG Molecular Diagnostics, Inc.; Tuscon, AZ, USA) was used to study 1050 mature miRNAs in human, rat, and mouse based upon the Sanger miRBase release 9.1.

Techniques: Quantitative Proteomics

Journal: Biology Open

Article Title: Effects of β4 integrin expression on microRNA patterns in breast cancer

doi: 10.1242/bio.20121628

Figure Lengend Snippet: GeneChip derived mRNA levels were ranked from the most upregulated in β4 transfected cells to the most downregulated (x-axis, 1 to 12,300, respectively). Red shading indicates mRNA is upregulated in β4 transfectants, while blue shading indicates mRNA is downregulated. Each vertical black line represents a miRNA target. The left-to-right position of each black line indicates the relative position of the predicted target within the rank ordered mRNA list. ( A ) miR-92ab predicted target gene are enriched among mRNAs up-regulated in the β4 transfectants, as illustrated by the increasing number of black lines on the left side of each graphic and the positive running enrichment scores (ES) marked by the red lines (p = 0.028). No enrichment was detected for and miR-99ab/100. ( B ) miR-15abc/16/16abc/195/322/424/497/1907 (p = 0.039), miR-23abc/23b-3p (p = 0/034), miR-27abc/27a-3p (p = 0.003), and miR-30abcdef/30abe-5p/384-5p (p = 0.0) predicted target genes are enriched among mRNAs up-regulated in the β4 transfectants.

Article Snippet: A novel qNPA based miRNA Microarray high throughput platform from High Throughput Genomics (HTG Molecular Diagnostics, Inc.; Tuscon, AZ, USA) was used to study 1050 mature miRNAs in human, rat, and mouse based upon the Sanger miRBase release 9.1.

Techniques: Derivative Assay, Transfection